MC2 Therapeutics A/S Completes Enrollment of EU Phase 3 Head-to-Head Study in Patients With Plaque Psoriasis Treated With MC2-01 PADTM Cream
MC2 Therapeutics A/S, a late clinical-stage pharmaceutical company focused on topical therapies for chronic inflammatory conditions, today announced the completion of enrollment for its EU Phase 3 study assessing the safety and efficacy of MC2-01 PAD™ Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) in adult patients with plaque psoriasis compared to Daivobet® gel (marketed in the US as Taclonex® Topical Suspension).
“Completion of patient enrollment in this EU Phase 3 registration study marks yet another significant and timely accomplishment for the MC2-01 PAD™ Cream global development program in plaque psoriasis following our successful US Phase 3 head-to-head study in 2018, ” stated Jesper J. Lange, CEO & President of MC2 Therapeutics. He added: “Our efforts in both EU and US demonstrate that we are committed to build leadership in topical therapies for patients with chronic inflammatory conditions. Our proprietary PAD™ Technology enables us to develop a new standard of topical therapies that combine fast and effective relief of symptoms with a unique moisturizing and cosmetic feel that we believe will significantly upgrade the patient experience and convenience in daily routines.”
About the MC2-01 PAD™ Cream Phase 3 Study
The study is a Phase 3, randomized, multicenter, investigator-blind, parallel-group study to evaluate the efficacy and safety of MC2-01 PAD™ Cream in subjects with plaque psoriasis compared to MC2-01 vehicle and Daivobet® gel. Subjects apply study medication topically once daily for up to 8 weeks. The primary objective is to show therapeutic superiority of MC2-01 PAD™ Cream to the active comparator, as well as to characterize the safety profile of MC2-01 PAD™ Cream in subjects with plaque psoriasis. The primary efficacy endpoint is percentage change from baseline in mPASI on the body at Week 8. The study enrolled 490 patients in 32 centres in Europe.
About MC2 Therapeutics A/S
MC2 Therapeutics A/S is a privately held late clinical-stage pharmaceutical company focused on topical therapies for chronic inflammatory conditions. Using its proprietary PAD™ Technology – a unique oil-in-water dispersion – MC2 Therapeutics is developing a pipeline of novel innovative topical therapies designed for unique patient experiences.
For additional information on MC2 Therapeutics Group, please visit www.mc2therapeutics.com
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-GILEAD-SCIENCES23.8.2019 22:03:10 CEST | Press release
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
CA-ANDERSEN-TAX23.8.2019 14:18:12 CEST | Pressemeddelelse
Andersen Global debuterer i Colombia
KERING23.8.2019 09:49:11 CEST | Press release
32 Leading Global Fashion and Textile Companies Make Commitments on Climate, Biodiversity and Oceans
BITFLYER23.8.2019 07:02:02 CEST | Press release
Ethereum (ETH) Now Available on bitFlyer Buy/Sell
STALICLA23.8.2019 02:02:11 CEST | Press release
STALICLA Announces Completion of pre-IND Meeting With FDA on STP1 for Subgroup of Patients With Autism Spectrum Disorder (ASD)
NV-RIMINI-STREET,-INC.23.8.2019 00:02:07 CEST | Press release
San Fang Chemical Switches to Rimini Street Support for its Oracle EBS and Oracle Database Software
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom